Shares of Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $56.20.
A number of research firms recently commented on TEM. Guggenheim assumed coverage on shares of Tempus AI in a research note on Monday. They issued a “buy” rating and a $74.00 price objective for the company. Bank of America cut Tempus AI from a “buy” rating to a “neutral” rating and raised their target price for the stock from $45.00 to $60.00 in a research report on Wednesday, October 2nd. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and upped their price target for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Piper Sandler restated a “neutral” rating and set a $70.00 price objective (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, Loop Capital upped their target price on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, October 15th.
Check Out Our Latest Research Report on Tempus AI
Institutional Trading of Tempus AI
Tempus AI Stock Down 3.2 %
TEM stock opened at $45.00 on Friday. The firm’s 50-day moving average price is $53.18. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI has a one year low of $22.89 and a one year high of $79.49.
About Tempus AI
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Further Reading
- Five stocks we like better than Tempus AI
- What is a Special Dividend?
- Survey Reveals: Which States Saw the Biggest Investment Gains in 2024?
- How to Read Stock Charts for Beginners
- Amazon’s Healthcare Gamble: A New Era of Medical Disruption
- Following Congress Stock Trades
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.